My cart

You have no items in your shopping cart.

About The Qurr Movement

Read More
  • About qurr
    Who We Are:
    The Qurr movement is led by a network of leading scientists, clinicians, trainers, thought leaders, and consumers who all believe in the critical role of muscle in overall well being.
    Why Qurr?
    Simply Put: Healthy muscles equal strong bodies, and strong bodies allow us to lead healthier lives even in the face of physical challenges. Whether you want to get stronger, more fit, recover faster, or have a faster metabolism, Fortetropin® is the key to overcoming your bodies’ current limitations.
    What is Fortetropin®?
    Fortetropin® is built on an understanding of a problematic chemical that most people don’t know that they have in their bodies, Myostatin. Myostatin hinders muscle growth, but with Myostatin properly managed, the opportunity to build muscle thickness and lean body mass dramatically increases, allowing users to gain muscle faster, and fight muscle loss which traditionally would be very difficult to achieve. Fortetropin® is the first safe, all-natural Myostatin reducing agent available, and it is clinically proven to build lean muscle mass and thickness with the proper training.
    Benefits of Fortetropin®:

    Fortetropin® improves protein utilization which allows one to increases muscle size faster than protein alone.

    Fortetropin® is clinically proven to help build lean muscle mass.

    Fortetropin® promotes muscle health.

  • Qurr movement
    “Qurr is muscle health”
    • Qurr is a movement to make our bodies stronger and live a healthier life.
    • Qurr is a movement which uses natural proteins and lipids to help support skeletal muscle mass and size.
    • Qurr is a movement for better lives and healthier bodies.
    • Qurr is muscle growth.

    Qurr is the beginning of a new movement where muscle health is at the core of one’s healthy lifestyle. Our goals are to educate consumers while providing products that support healthy lean muscle for both men and women.

    Our belief is that optimum health includes a healthy mind as well as a healthy body. Healthy muscle is a key contributor to sustaining optimum health.

    We have developed Qurr product lines to meet the needs of four demographic groups to help them achieve optimum muscle health.

    “Fortetropin® is comprised of bioactive molecules isolated from natural fertilized egg yolks using a patented proprietary process that preserves the biological integrity and bioactivity of the mixture.”

  • Science
    • Fortetropin improves body’s utilization of protein, it helps you build lean and healthy muscle faster than with protein alone. Fortetropin is not a steroid and is not an artificial supplement.
    • Fortetropin® is a bioactive proteo-lipid complex containing various proteins, lipids, peptides and other bioactive molecules isolated from fertilized egg yolk using a patented proprietary process that preserves the biological integrity and bioactivity of the mixture.
    • Fortetropin® is the first safe, all-natural Myostatin reducing ingredient. Fortetropin® reduces Myostatin in your body which impedes muscle growth. A clinical study on Fortetropin® showed positive effects on both muscle thickness and lean body mass compared to placebo.
    • No adverse events reported during any studies.
    • Study publications available here.
  • All natural ingridients
    “Our ingredients are simple, pure, and scientifically formulated to help make your body strong and healthy.”
    • Despite the results, our products do not include any supplements or steroids in our products.
    • Low in calories and carbs! Our powder uses less than 60 calories and less than 4 grams of carbs. Our shakes/puddings contain 160 calories, 20 grams of protein, and less than 10 grams of carbs.
    • Nothing to hide! Our proprietary ingredient (Fortetropin®) is made from natural fertilized eggs, the only natural Myostatin reducing agent currently on the market. Fortetropin® is 100% natural fertilized egg yolk powder produced via a proprietary process that preserves the biological integrity and bioactivity of the mixture. All of our products are non-GMO and gluten free. Our products use non high-fructose corn syrup sweeteners such as Stevia for optimal flavor, health and taste. Our products contain no artificial chemicals or additives.
    • Individual nutrition facts and ingredient listings available on product pages.
  • Joseph Mannello
  • Maghsoud Dariani
  • Dominick Commesso
  • Neerav Dilip Padliya
  • Joanne Goodford
  • Joseph DiPietro
  • Alex Tess
  • Dr. Robert Hariri
Joseph Mannello

Joseph Mannello, Interim Chief Executive Officer, has served as a consultant since May 2015. From March 2013 to May 2015, he served as the executive managing director at Brean Capital LLC, an independent investment bank and asset management firm, where he also served as a member of the firm’s operating committee. From March 2008 to March 2012, Mr. Mannello was the head of corporate credit for Gleacher & Company, Inc. (OTC:GLCH), a publicly-traded investment bank. Prior to that, he was the head of the fixed income division of BNY Capital Markets, Inc., a subsidiary of The Bank of New York Mellon Corp. (NYSE:BK). We believe Mr. Mannello’s extensive financial markets background qualifies him to serve on our Board of Directors.

Joseph Mannello
Joseph Mannello, Interim Chief Executive Officer, has served as a consultant since May 2015. From March 2013 to May 2015, he served as the executive managing director at Brean Capital LLC, an independent investment bank and asset management firm, where he also served as a member of the firm’s operating committee. From March 2008 to March 2012, Mr. Mannello was the head of corporate credit for Gleacher & Company, Inc. (OTC:GLCH), a publicly-traded investment bank. Prior to that, he was the head of the fixed income division of BNY Capital Markets, Inc., a subsidiary of The Bank of New York Mellon Corp. (NYSE:BK). We believe Mr. Mannello’s extensive financial markets background qualifies him to serve on our Board of Directors.
Maghsoud Dariani
Maghsoud Dariani, Science and Technology, has over 30 years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani has a successful record of business management, strategic planning, acquisition and divestiture, project management, production management, R&D management, economic evaluations, competitor analyses, and development and administration of multi-million dollar budgets. Mr. Dariani is also an entrepreneurial business leader with a sound grasp of successful business strategies, with an excellent foundation in science and engineering, and a strong background in product development and commercialization.   As President & CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer, Mr. Dariani is responsible for overall management of the business and R&D, as well as securing capital for operations.  Prior to joining Semorex, Mr. Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage then successfully negotiated the sale of the company in February 2003.  Prior to Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation.  During his twelve years at Celgene, Mr. Dariani developed and implemented Celgene’s manufacturing strategy, managed and successfully sold Celgene’s chiral intermediates business unit, and formulated a strategic plan for leveraging Celgene’s expertise in chiral technologies towards the development of chirally pure drug products.  Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names. Prior to Celgene, Mr. Dariani held progressively more responsible engineering and development positions at Celanese Corporation.  Mr. Dariani holds a BS degree from The City College of NY and a MS degree from University of Massachusetts in Chemical Engineering.  Mr. Dariani is a member of Board of Directors at Semorex Inc. and Mesa Therapeutics.
Dominick Commesso
Dominick Commesso, Executive Vice President of Sales and Marketing, joined Myos in February, 2016 to spearhead sales and marketing.  Mr. Commesso is joining Myos after a very successful  23-year career on Wall Street as an equity sales trader, working on many different institutional size platforms from Credit Suisse to Alex Brown. He brings his well diversified wall street skill set and deep client relationships to MYOS corp.  Mr. Commesso is a lifetime athlete who played soccer at the Division 1 college level for University of North Carolina at Charlotte and has coached at the youth level up to High School. His Passion for health, fitness and financial background will help drive global sales and challenge the team every day to be better.
Neerav Dilip Padliya
Neerav Dilip Padliya, PhD, PMP is Vice President, Research Alliances at MYOS RENS Technology Inc. His career success began in 2006 at Celgene Corporation where he was the Principal Investigator behind a highly interdisciplinary program focused on mass spectrometry-based proteomic studies of placenta-derived populations of stem cells and natural killer cells. Dr. Padliya spearheaded collaborations with Immunologists and Cell Biologists that led to the issue of two U.S. patents, one pending U.S. patent application and the publication of one journal article as senior author. In 2011, Dr. Padliya joined AB SCIEX, (a wholly owned operating company of Danaher Corporation) a premier manufacturer of high-end mass spectrometry instrumentation used for applications in pharmaceuticals, clinical laboratories, environmental monitoring and the food and beverage industry. Prior to joining MYOS RENS Technology Inc., Dr. Padliya worked closely with the North American Sales Force at AB SCIEX to perform several winning demonstrations of accurate mass, high-resolution mass spectrometers that paved the way for new business opportunities with major pharmaceutical and biotechnology accounts. Dr. Padliya graduated with a B.Sc. (Honors), Chemistry in 2001 from McMaster University (Canada) and graduated with a PhD in Analytical Chemistry in 2005 from the State University of New York at Buffalo (USA). Dr. Padliya is the author of five peer-reviewed publications as first author and an inventor on two U.S. patents and one pending U.S. patent application. Dr. Padliya has served as a reviewer for well-reputed journals such as Anal. Chimica Acta, Anal. Methods, Integrative Biology, and Molecular Biosystems.
Joanne Goodford
Joanne Goodford, Operations, Facility Development Manager, has more than 25 years of management experience, with six years in project operations during contract start-up phases on government initiatives in a healthcare setting.  Her role included office facilities build-outs, floor plan development, quality assurance, establishing processes and workflows, recruiting, hiring and training of staff.  Ms. Goodford also served on several proposal development teams which had a 100% win rate and included responding to a $350m contract for the state of Georgia. With an eye to quality outcomes, timely project completion and cost management, Ms. Goodford served as Project Manager for the build-out of MYOS RENS’ corporate offices bringing the project in under budget and under deadline.  Ms. Goodford holds a BS from Montclair State University.
Joseph DiPietro
Joseph DiPietro, Controller, joined Myos in September 2016. Mr. DiPietro was most recently the CFO at the Harlem School of the Arts in New York. He graduated St. John’s University in 1988 with a BS in Accounting. He obtained his CPA license while working as an auditor for McGladrey (RSM). He has held positions such as VP Finance, Controller, and Director of Financial Reporting at a few public companies such as Pfizer, Celgene, Juno Online, Majesco, Audible and Turtle Beach.
Alex Tess
Alex Tess, Quality Assurance Manager, is responsible for implementing and maintaining the effectiveness of the quality system at MYOS RENS Technology Inc. He successfully runs programs that ensure all specifications for products or services are met and monitors progress and compliance through regular inspections. Mr. Tess develops standard operating procedures and manages stability studies, ensuring compliance with protocols. Prior to joining MYOS RENS Technology Inc., Mr. Tess worked as a research associate at Celgene Cellular Therapeutics exploring platforms for cell-based therapies in the therapeutic areas of cancer and inflammatory diseases. He excelled in establishing methods for differentiation of various cell lines form mesenchymal stem cells as well as characterizing and monitoring cell lines for comprehensive in vitro studies. Mr. Tess has a BS in Biochemistry from Fairleigh Dickinson University as well as a BS degree from Kazan Aviation University in Aircraft Engineering. In addition, Mr. Tess has completed Pharmaceutical Quality Assurance and Control Trainings.
Dr. Robert Hariri
Our team is headed by Dr. Robert Hariri a world renowned academic and pharmaceutical inventor. Dr. Robert Hariri has more than 100 issued and pending patents and over 100 published chapters and articles and abstracts. Dr. Robert Hariri has pioneered the use of cells and biomaterials to treat a wide range of life threatening diseases. Dr. Hariri was the recipient of the Thomas Alva Edison award in 2007 and 2011. Dr. Hariri was previously the founder, chief scientific officer, and chairman of Celgene Cellular Therapeutics. We are a publicly traded company (MYOS Rens Technology) which is responsible for making full & transparent reports of what we do and how we do it. Our management team, board of directors, and scientific board contain more than a half-dozen doctors (both MDs and PHDs).
Ren Ren
Ren Ren has more than 28 years of experiences in China’s food and agricultural business. Since 2001, he formed and operated Beijing Seasons Investment Group Co, Ltd and RENS Agriculture Science and Technology Co, Ltd. Mr. Ren is also chairman of China’s Nutrition and Health Guidance Committee, Editor in Chief of The Capital Food Safety Weekly, chairman of Beijing Seasons Investment Group Co., Ltd, chairman of Anhui Woyang Huadu Properties Co., Ltd., chairman of Xingguo Hongtianxia Camellia Oil Co., Ltd, and chairman of Nanjing Xingfeng Ecological Agriculture Co., Ltd. From 1993 to 2001, he formed and operated multiple companies in Nanchang, Jiangxi Province, mainly engaged in agricultural products operation and management. From 1987 to 1992, he was a department director at Sheyang Food Bureau, responsible for grain purchasing and management. We believe Mr. Ren’s extensive knowledge and experience with respect to health and nutrition products and his extensive food product industry background qualifies him to serve on our Board of Directors.
Bin Zhou
Bin Zhou is an attorney licensed in the State of New Jersey. Since November 2007, he has been an attorney and a partner at Bernard & Yam, LLP, a New York law firm. He has advised companies on their public listings on U.S. stock exchanges including NASDAQ, NYSE and OTC markets, as well as on their private and public offering of securities. He received a bachelor’s degree in Economic Laws from Nanjing University, China, in 2001. He received a Master of Social Work from University of Georgia in 2003 and a Juris Doctor’s degree from Rutgers University School of Law in 2006. We believe Mr. Zhou’s extensive background in corporate compliance and international law qualifies him to serve on our Board of Directors.
Dr. Louis Aronne
Dr. Louis Aronne joined us as a Director and a member of our Scientific Advisory Board in July 2011. Dr. Aronne is the Weill Professor of Metabolic Research and Director of the Comprehensive Weight Control Center which he founded in 1986 at Weill-Cornell Medical College. He is an Adjunct Clinical Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Aronne is former president of the Obesity Society and a fellow of the American College of Physicians. He has been an investigator on more than 40 trials, authored more than 60 papers and book chapters on obesity and edited the National Institutes of Health Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Dr. Aronne has won several awards for teaching, including the Leo M. Davidoff Society Prize from Albert Einstein College of Medicine in 1983 and Eliot Hochstein Teaching Award from Cornell University in 1990. Dr. Aronne graduated Phi Beta Kappa from Trinity College with a BS in biochemistry and from Johns Hopkins University School of Medicine. We believe Dr. Aronne’s skills as a physician and his knowledge and experience with respect to obesity and related metabolic diseases qualifies him to serve on our Board of Directors.
Christopher Pechock
Christopher Pechock joined us as a Director in February 2014. Mr. Pechock has been a partner at Matlin Patterson Global Advisers, a global alternative asset manager, since its inception in July 2002. From November 1998 to July 2002, Mr. Pechock served as a member of the Global Distressed Securities Group Credit Suisse (NYSE:CS). From January 1997 to October 1998, Mr. Pechock served as a Portfolio Manager and Research Analyst at Turnberry Capital Management, L.P. Prior to that, Mr. Pechock served as a Portfolio Manager at Eos Partners, L.P. (February 1996 to December 1996), a Vice President and high yield analyst at PaineWebber Inc. (May 1993 to January 1996) and an analyst in risk arbitrage at Wertheim Schroder & Co., Incorporated (August 1987 to April 1991). He serves on the board of directors of Gleacher & Company, Inc. (NASDAQ: GLCH), and Oceanus LLC, a private ship-owning company. Mr. Pechock received a BA in Economics from the University of Pennsylvania and an MBA from the Columbia University Graduate School of Business. We believe Mr. Pechock’s extensive financial background qualifies him to serve on our Board of Directors.
Victor Mandel
Victor Mandel joined us as a director in August 2016 and previously served as a director of the Company from December 2015 until March 2016. He has over twenty-five years of experience in investments, corporate strategy and corporate governance. Mr. Mandel previously served as Co-Chairman of Ambac Financial Group, Inc. (NASDAQ: AMBC) from May 2013 through December 2014 and as a director, chair of its Governance and Nominating Committee and member of its Audit and Strategy and Risk Policy Committees from May 2013 until May 2016. Additionally, he has previously served as a member of the board of directors and on the audit committees of Comsys IT Partners, Inc. (acquired by ManpowerGroup Inc.), Broadpoint Gleacher Securities Group, Inc., and XLHealth Corp. (acquired by UnitedHealth Group Inc.). He previously served as the Chief Financial Officer of Circle.com (NASDAQ:CIRC) and served as Executive Vice President, Finance and Development of Snyder Communications, Inc. (acquired by Havas Group) from 1999 to 2000. From 1991 to 1999, Mr. Mandel served as vice president in the Investment Research department at Goldman Sachs & Co. (NYSE:GS). Mr. Mandel holds an MBA in Finance from the Wharton School of Business at the University of Pennsylvania, an A.B. in Computer Science from Harvard University, and is a Chartered Financial Analyst. We believe Mr. Mandel’s extensive financial background qualifies him to serve on our Board of Directors.
John J. Nosta
Mr. Nosta was re-elected to the Myos Rens Board in December 2016. He is the founder of NOSTALAB—a digital health think-tank and marketing consulting company. A leading voice in the convergence of technology and health, Mr. Nosta helps define, dissect and deliberate global trends in digital health. He is consistently ranked among the top names in almost every digital health list and has sustained that position for several years. Beyond simply an influencer, he is also defined as “most admired” to “top disruptor” in digital health, life sciences and the pharmaceutical industry. As a member of the Google Health Advisory Board, Mr. Nosta has penned HEALTH CRITICAL for Forbes--a top global blog on health and technology. For over 20 years, he was part of leadership of leading healthcare communication companies for Omnicom and WPP. Prior to founding NOSTALAB, Mr. Nosta was employed by Ogilvy CommonHealth (WPP) for 10 years from 2003 to 2013, where he held a series of positions including Chief Creative Officer, Chief Strategic Officer, and unit President. Prior to this, he held various senior level positions at LLNS (Omnicom) from 1990 to 1997. Earlier in his career, Mr. Nosta was a research associate at Harvard Medical School and co-authored several papers with global thought-leaders in the field of cardiovascular physiology. He received a Bachelor of Arts degree from Boston University in 1981. We believe Mr. Nosta’s extensive professional background, including his global marketing and medical experience qualifies him to serve on our Board of Directors.
Dr. Caroline Apovian
Dr. Caroline Apovian joined the Scientific Advisory Board in February 2013, and is Professor of Medicine and Pediatrics, in the Section of Endocrinology, Diabetes, and Nutrition at Boston University School of Medicine, USA. She is also Director of the Center for Nutrition and Weight Management at Boston Medical Center, USA. Dr. Apovian is a nationally and internationally recognized authority on Nutrition and Obesity Medicine and has been in the field of Obesity and Nutrition since 1990. Her current research interests are in: weight loss and its effects on endothelial cell function obesity and cardiovascular disease, adipose cell metabolism and inflammation, resolution of diabetes and cardiovascular disease in the bariatric surgery population, disparities in the treatment of obesity in underserved populations and novel pharmacotherapeutic antiobesity agents. She is also an expert in the technique for subcutaneous adipose tissue biopsies, and has been studying the relationship between adipose tissue inflammation and obesity for over 10 years. Dr. Apovian was a member of the expert panel for updating the 2013 AHA/ACC/TOS Clinical Guidelines for the Management of Overweight and Obesity in Adults, published in CIRCULATION and OBESITY journals and was the Chair of the Endocrine Society guidelines for Medical Treatment of Obesity published in the Journal of Endocrinology and Metabolism in 2015. Dr. Apovian was a recipient of the Physician Nutrition Specialist Award given by the American Society of Clinical Nutrition. This was for her work on developing and providing nutrition education, to medical students and physicians in training at Boston University School of Medicine. She has published over 200 original peer-reviewed articles, chapters, and reviews on the topics of: obesity, nutrition, and the relationship between adipose tissue and risk of developing cardiovascular disease. Dr. Apovian has given over 150 invited lectures nationally and internationally and currently serves as President Elect of The Obesity Society (TOS) for 2016-17.
Dr. Neilank Jha
Dr. Neilank K. Jha was born in Edmonton, Alberta and grew up playing hockey in Regina, Saskatchewan. At an early age, Dr. Jha travelled to an ashram in India for 5 years where he was trained in meditation and yoga and had the privilege of playing soccer with people from around the globe. Dr. Jha is the Founder of the KONKUSSION program. His vision is to revolutionize and redefine the management of concussions. He has assembled at the KONKUSSION program what he describes as "one of the best teams in sports" to tackle this challenging issue of concussions from both a clinical and research perspective. www.konkussion.com He pursued his undergraduate studies at the University of Toronto, completed his medical school training at McMaster, completed a 6 year residency in neurosurgery at McMaster University and subsequently completed a two year fellowship from the University of Toronto in complex spinal disorders. He is a board certified Neurosurgeon FRCS(C) and a fellowship trained Spine Surgeon. Dr. Jha is one of the international concussion experts, participating in multiple national level interviews and press conferences with CBC, CTV and Global, regarding head and spine injuries in sports; was invited to the House of Commons and Parliament to meet with federal leaders regarding this issue; is a Political consultant for federal leaders on national strategy; and was a consultant for The Hockey News, in: "Fighting the Good Fight: Why On-Ice Violence is Killing Hockey", by Adam Proteau (John Wiley & Sons, October 18, 2011). Dr. Jha has published numerous articles, papers and book chapters, as well as presenting various abstracts at scientific meetings in Canada and the United States. Dr. Jha is also the recipient of the Best Paper Award, NASS (North American Spine Society), For: "Cost effective analysis of CSM (cervical spondylitic myelopathy) Surgery", Chicago, Illinois, November 2011. Dr. Jha is the Editor in Chief of Current Research: Concussion, a global medical journal. Current Research: Concussion aims to bridge the gap between concussion awareness and knowledge. Publishing peer-reviewed articles, this Open Access journal strives to provide a medium for researchers around the globe to share their work, and for practitioners to remain on the cutting edge of management. Large, multi-centered clinical trials to determine the potential efficacy of concussion treatments and diagnostic tools are a focus of the journal. The ultimate objective is to provide robust clinical data for an evidence-based approach to concussion management.
  • Ren Ren
  • Bin Zhou
  • Dr. Louis Aronne
  • Christopher Pechock
  • Victor Mandel
  •  John J. Nosta
  • Dr. Caroline Apovian
  • Dr. Neilank Jha